We thank our colleagues Hui and Lee for their Correspondence (Mechanical occlu sion of the left atrial appendage — lessons from surgical experience. Nat. Rev. Cardiol. https://doi.org/10.1038/nrcardio.2018.7; 2018)1 on our… Click to show full abstract
We thank our colleagues Hui and Lee for their Correspondence (Mechanical occlu sion of the left atrial appendage — lessons from surgical experience. Nat. Rev. Cardiol. https://doi.org/10.1038/nrcardio.2018.7; 2018)1 on our Review (Caliskan, E. et al. Interventional and surgical occlusion of the left atrial appendage. Nat. Rev. Cardiol. 14, 727–743; 2017)2. Indeed, including in our Review an analysis of particular failure modes of different left atrial appendage (LAA) closure techniques and devices would have been interesting, but was beyond the scope of our article. We acknowledge the consider ations by Hui and Lee on the anatomical and procedural complexities of achieving com plete LAA closure, which is, however, also mentioned in our Review. Second, we respectfully disagree with the authors’ statements and opinion regard ing the AtriClip1. Our overall conclusions and confidence in the AtriClip device are not only drawn from the referenced study3, but are also based on numerous pre clinical and clinical studies that have systemati cally evaluated the AtriClip for its safety and efficacy profile over the past decade4–7. Indeed, initial experiences from our own firstinhuman pilot trial7 and the multi centre EXCLUDE trial4 with systematic imaging followup (either trans oesophageal echocardiography (TEE) or CT imaging) clearly demonstrated the safety and effi cacy of the AtriClip. These findings were further validated in our 3year CTimaging followup report showing the stability and durability of the AtriClip, with no thrombus formation at the stump5. Moreover, a study published in 2017 including 101 patients with a followup of 18 ± 11 months using TEE or CT further confirmed these results6. Importantly, these studies also highlight that AtriClipenabled LAA closure is dur able when complete TEEguided occlusion is achieved intraoperatively. In the referenced study from our centre (which also states the potential limitations of the study)3, we have further validated the longterm safety, efficacy, and durabil ity of the AtriClip in an additional large cohort (including the firstinhuman trial cohort and all consecutive patients thereafter). Notably, neither in this study3 nor in our ongoing clinical programme have we ever experienced any impairment of the circumflex artery while achieving complete LAA closure with the AtriClip. On the basis of this continu ously increasing and supporting evidence on the AtriClip (with currently >100,000 devices sold and applied worldwide), we strongly advocate for a deviceenabled epicardial closure strategy to achieve safe, complete, and durable LAA closure. Third, we generally agree with the com ment by Hui and Lee on the importance of a residual stump after surgical LAA closure and, in accordance with current clinical recommendations, the maximum stump length should not exceed 10 mm (REFS 8–11). However, we consider this cutoff to be a threshold, and we aim in all our patients to stay substantially <10 mm or to have no stump at all. Indeed, brief preliminary analy sis of our patients with available CT data (which is part of an ongoing separate study) shows that the majority of patients (>70%) present with no detectable stump, whereas the rest present with a stump length substan tially <10 mm. Importantly, we want to high light that the AtriClipenabled LAA closure creates an almost smooth line of occlusion by endocardial adaptation if applied appropri ately. We and others have demonstrated this mode of closure in preclinical studies12–14. As such, the thrombogenicity profile of this AtriClipenabled closure cannot be directly compared with a true culdesac, as seen after sutured or ligated LAAs as reported by Hui et al.15. Additionally, and as per defin ition, the ostium and the neck of the LAA do not contain pectinate muscles and, therefore, can be considered fairly safe with regard to thrombogenicity10. We, however, share the authors’ opinion that clear recommendations on cessation of oral anticoagulant therapy after LAA closure are urgently needed. Finally, we respectfully disagree that we might have neglected to mention contempor ary papers in our Review. The mentioned randomized clinical pilot trial (authored Lee) including 28 patients demonstrated that stapled excision, surgical excision, and surgi cal ligation of the LAA are associated with highly heterogeneous success rates and come with different modes of failure16. However, because these results have been known for more than a decade8,17–19, we did not consider these findings to add any substantial new information to the contemporary field of surgical LAA closure.
               
Click one of the above tabs to view related content.